GLPG — Galapagos N.V.

Summary of Galapagos Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Operating Loss: For the first nine months of 2025, Galapagos reported an operating loss of EUR 462.2 million, significantly higher than the EUR 125.6 million loss in the same period of 2024. This loss was impacted by a EUR 204.8 million impairment related to the cell therapy business and EUR 135.5 million in costs from a strategic reorganization.
• Net Financial Income: The company recorded net other financial income of EUR 30.4 million, down from EUR 71.7 million in 2024, primarily due to decreased interest income (EUR 31.4 million compared to EUR 70.6 million in 2024).
• Cash Position: As of September 30, 2025, cash and cash equivalents totaled EUR 3.05 billion, representing EUR 46 per share. The company anticipates ending 2025 with approximately EUR 2.975 billion to EUR 3.05 billion in cash.
• Future Cash Flow: Galapagos expects to achieve cash flow neutrality or positive status by the end of 2026, excluding any business development activities.

2. Strategic Updates and Business Highlights

• Cell Therapy Business Wind Down: Following a strategic review, the Board has decided to wind down the cell therapy business due to lack of viable acquisition proposals and significant ongoing investment requirements. This decision may impact approximately 365 employees across various locations.
• Pipeline Development: The company is focused on its TYK2 program, with Phase III enabling studies for SLE and dermatomyositis expected to yield data by early 2026, ahead of original timelines.
• Business Development Strategy: Galapagos is actively pursuing business development opportunities, particularly in oncology and immunology, leveraging its strong cash position and partnership with Gilead to identify and execute on promising programs.

3. Forward Guidance and Outlook

• Consultation Timeline: The wind-down process for the cell therapy business is expected to conclude in Q1 2026, following consultations with works councils in Belgium and the Netherlands.
• Business Development Focus: The company aims to utilize its significant cash reserves to pursue clinically derisked and differentiated opportunities, with an emphasis on partnerships that create mutual value with Gilead.

4. Bad News, Challenges, or Points of Concern

• Increased Operating Losses: The substantial increase in operating losses raises concerns about the financial health of the company, particularly in light of the impairment of the cell therapy business.
• Employee Impact: The wind-down of the cell therapy business will affect a significant number of employees, which may impact morale and operational capacity.
• Market Dynamics: The inability to find a buyer for the cell therapy business reflects challenging market conditions and could indicate broader issues within the biotech sector.
• Cash Flow Risks: While the company anticipates cash flow neutrality by the end of 2026, this is contingent on interest income and the successful completion of the wind-down process, which introduces uncertainty.

5. Notable Q&A Insights

• Cash Flow Neutrality Assumptions: The CFO indicated that the forecast for cash flow neutrality is based on interest income, tax credits, and the completion of the wind-down process, with no business development activities assumed.
• Deal Funnel Optimism: The leadership expressed confidence in the deal funnel, focusing on mid- to late-stage opportunities and emphasizing collaboration with Gilead to enhance value creation.
• Virology as a Priority: The company is currently prioritizing oncology and immunology over virology, although it remains open to opportunities in the latter area.
• Gilead Collaboration: There is a strong emphasis on the collaborative relationship with Gilead, which is expected to contribute both capital and expertise in the business development process.

Overall, while Galapagos is undergoing significant transformation and has a solid cash position, the challenges associated with the wind-down of its cell therapy business and increasing operating losses present notable risks to its future performance.